home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ACADIA Pharmaceuticals Inc. - Common Stock (NQ:ACAD)

20.61 -0.66 (-3.10%)

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about ACADIA Pharmaceuticals Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

18 19 Next >

Acadia Pharmaceuticals Announces Phase 3 Development Candidate ACP-101 (intranasal carbetocin) for Prader-Willi Syndrome

June 13, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Nature Medicine Publishes Results from Pivotal Phase 3 LAVENDER™ Study Evaluating DAYBUE™ (trofinetide) Efficacy and Safety in Patients with Rett Syndrome

June 08, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

3 Penny Stocks That Could Skyrocket in the Next 12 Months ↗

June 07, 2023

Find the top penny stocks to buy, and you can make a fortune. Pick the wrong one and there are also plenty of horrors.

Via InvestorPlace

Acadia Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

June 01, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA Pharmaceuticals's Return On Capital Employed Insights ↗

May 23, 2023

Via Benzinga

What 22 Analyst Ratings Have To Say About ACADIA Pharmaceuticals ↗

May 09, 2023

Via Benzinga

ACADIA Pharmaceuticals's Earnings: A Preview ↗

May 05, 2023

Via Benzinga

Over $5M Bet On Southwest Gas? Check Out These 4 Stocks Insiders Are Buying ↗

May 25, 2023

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

Via Benzinga

ACADIA ALERT: Bragar Eagel & Squire, P.C. is Investigating Acadia Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

May 24, 2023

From Bragar Eagel & Squire, P.C.

Via Business Wire

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Records 52-Week High Tuesday Morning

May 23, 2023

Via Investor Brand Network

Top 5 Health Care Stocks That Should Keep You Up At Night ↗

May 23, 2023

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

April 14, 2023

Via Benzinga

Analyst Ratings for ACADIA Pharmaceuticals ↗

March 20, 2023

Via Benzinga

Acadia Pharma's Rett Syndrome Drug Becomes First FDA-Approved Treatment ↗

March 13, 2023

Via Benzinga

1 Top Biotech Stock to Buy in March ↗

March 07, 2023

This biotech could land a major regulatory approval this month.

Via The Motley Fool

Acadia Pharmaceuticals Reports First Quarter 2023 Financial Results and Operating Overview

May 08, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

May 05, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at Upcoming Investor Conferences

May 02, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2023

April 25, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present DAYBUE™ (trofinetide) Clinical Data and Rett Syndrome Real World Evidence at the 2023 American Academy of Neurology (AAN) Annual Meeting

April 20, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Why ACADIA Pharmaceuticals (ACAD) Shares Are Trading Higher ↗

April 17, 2023

ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) shares are trading higher by 6.23% to $19.11 Monday morning after the company announced the availability of DAYBUE for treatment of Rett syndrome. What Else?

Via Benzinga

Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome

April 17, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

Acadia Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference

April 11, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector ↗

March 15, 2023

To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.

Via InvestorPlace

Acadia Pharmaceuticals Gets Price Target Bumps By Analysts After FDA Approval Of Rett Syndrome Drug ↗

March 14, 2023

The FDA approved Acadia Pharmaceuticals Inc's (NASDAQ: ACAD) Daybue (trofinetide) for Rett syndrome in adult and pediatric patients two years of age and older.

Via Benzinga

Jabil To Rally Around 23%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

March 14, 2023

Raymond James raised the price target for Jabil Inc. (NYSE: JBL) from $84 to $100. Raymond James analyst Melissa Fairbanks maintained a Strong Buy rating. Jabil shares fell 0.7% to close at $81.35 on...

Via Benzinga

Why Provention Bio Shares Are Trading Higher By Over 260%; Here Are 20 Stocks Moving Premarket ↗

March 13, 2023

Gainers Provention Bio, Inc. (NASDAQ: PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of...

Via Benzinga

3 Nasdaq Stocks on Watch This Week ↗

March 12, 2023

These three Nasdaq stocks are poised to make big moves in the coming week.

Via The Motley Fool

Acadia Pharmaceuticals Announces U.S. FDA Approval of DAYBUE™ (trofinetide) for the Treatment of Rett Syndrome in Adult and Pediatric Patients Two Years of Age and Older

March 10, 2023

From Acadia Pharmaceuticals Inc.

Via Business Wire

ACADIA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of ACADIA Pharmaceuticals Inc. - ACAD

March 03, 2023

From Kahn Swick & Foti, LLC

Via Business Wire

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com